533 related articles for article (PubMed ID: 28923906)
1. Effects of the Selective Sodium-Glucose Cotransporter 2 Inhibitor Empagliflozin on Vascular Function and Central Hemodynamics in Patients With Type 2 Diabetes Mellitus.
Striepe K; Jumar A; Ott C; Karg MV; Schneider MP; Kannenkeril D; Schmieder RE
Circulation; 2017 Sep; 136(12):1167-1169. PubMed ID: 28923906
[No Abstract] [Full Text] [Related]
2. How does empagliflozin improve arterial stiffness in patients with type 2 diabetes mellitus? Sub analysis of a clinical trial.
Bosch A; Ott C; Jung S; Striepe K; Karg MV; Kannenkeril D; Dienemann T; Schmieder RE
Cardiovasc Diabetol; 2019 Mar; 18(1):44. PubMed ID: 30922297
[TBL] [Abstract][Full Text] [Related]
3. Effects of Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter-2 Inhibitors, and Their Combination on Endothelial Glycocalyx, Arterial Function, and Myocardial Work Index in Patients With Type 2 Diabetes Mellitus After 12-Month Treatment.
Ikonomidis I; Pavlidis G; Thymis J; Birba D; Kalogeris A; Kousathana F; Kountouri A; Balampanis K; Parissis J; Andreadou I; Katogiannis K; Dimitriadis G; Bamias A; Iliodromitis E; Lambadiari V
J Am Heart Assoc; 2020 May; 9(9):e015716. PubMed ID: 32326806
[TBL] [Abstract][Full Text] [Related]
4. Design of a randomised controlled trial of the effects of empagliflozin on myocardial perfusion, function and metabolism in type 2 diabetes patients at high cardiovascular risk (the SIMPLE trial).
Jürgens M; Schou M; Hasbak P; Kjær A; Wolsk E; Zerahn B; Wiberg M; Brandt NH; Gæde PH; Rossing P; Faber J; Inzucchi S; Gustafsson F; Kistorp CM
BMJ Open; 2019 Nov; 9(11):e029098. PubMed ID: 31780586
[TBL] [Abstract][Full Text] [Related]
5. Population Pharmacokinetic- Pharmacodynamic Analysis to Characterize the Effect of Empagliflozin on Renal Glucose Threshold in Patients With Type 1 Diabetes Mellitus.
Mondick J; Riggs M; Kaspers S; Soleymanlou N; Marquard J; Nock V
J Clin Pharmacol; 2018 May; 58(5):640-649. PubMed ID: 29251772
[TBL] [Abstract][Full Text] [Related]
6. Effect of empagliflozin on coronary microvascular function in patients with type 2 diabetes mellitus-A randomized, placebo-controlled cross-over study.
Suhrs HE; Nilsson M; Bové KB; Zander M; Prescott E
PLoS One; 2022; 17(2):e0263481. PubMed ID: 35148357
[TBL] [Abstract][Full Text] [Related]
7. Empagliflozin on top of metformin treatment improves arterial function in patients with type 1 diabetes mellitus.
Lunder M; Janić M; Japelj M; Juretič A; Janež A; Šabovič M
Cardiovasc Diabetol; 2018 Dec; 17(1):153. PubMed ID: 30509271
[TBL] [Abstract][Full Text] [Related]
8. Analysis from the EMPA-REG OUTCOME
Mayer GJ; Wanner C; Weir MR; Inzucchi SE; Koitka-Weber A; Hantel S; von Eynatten M; Zinman B; Cherney DZI
Kidney Int; 2019 Aug; 96(2):489-504. PubMed ID: 31142441
[TBL] [Abstract][Full Text] [Related]
9. The effect of empagliflozin on oxidative nucleic acid modifications in patients with type 2 diabetes: protocol for a randomised, double-blinded, placebo-controlled trial.
Larsen EL; Cejvanovic V; Kjær LK; Vilsbøll T; Knop FK; Rungby J; Poulsen HE
BMJ Open; 2017 May; 7(5):e014728. PubMed ID: 28490557
[TBL] [Abstract][Full Text] [Related]
10. Rationale and design of a multicenter placebo-controlled double-blind randomized trial to evaluate the effect of empagliflozin on endothelial function: the EMBLEM trial.
Tanaka A; Shimabukuro M; Okada Y; Taguchi I; Yamaoka-Tojo M; Tomiyama H; Teragawa H; Sugiyama S; Yoshida H; Sato Y; Kawaguchi A; Ikehara Y; Machii N; Maruhashi T; Shima KR; Takamura T; Matsuzawa Y; Kimura K; Sakuma M; Oyama JI; Inoue T; Higashi Y; Ueda S; Node K;
Cardiovasc Diabetol; 2017 Apr; 16(1):48. PubMed ID: 28403850
[TBL] [Abstract][Full Text] [Related]
11. Postprandial Glucose and Triglyceride Increases Along with the Endothelial Malfunction were Attenuated by the Administration of SGLT2 Inhibitor, Empagliflozin.
Masuda D; Yamashita S
J Atheroscler Thromb; 2020 Jul; 27(7):637-638. PubMed ID: 32009076
[No Abstract] [Full Text] [Related]
12. Effect of empagliflozin on ketone bodies in patients with stable chronic heart failure.
Pietschner R; Kolwelter J; Bosch A; Striepe K; Jung S; Kannenkeril D; Ott C; Schiffer M; Achenbach S; Schmieder RE
Cardiovasc Diabetol; 2021 Nov; 20(1):219. PubMed ID: 34753480
[TBL] [Abstract][Full Text] [Related]
13. Effect of Empagliflozin and Dapagliflozin on Ambulatory Arterial Stiffness in Patients with Type 2 Diabetes Mellitus and Cardiovascular Co-Morbidities: A Prospective, Observational Study.
Patoulias D; Papadopoulos C; Zografou I; Katsimardou A; Karagiannis A; Doumas M
Medicina (Kaunas); 2022 Aug; 58(9):. PubMed ID: 36143844
[No Abstract] [Full Text] [Related]
14. Safety and effectiveness of empagliflozin in Japanese patients with type 2 diabetes: interim analysis from a post-marketing surveillance study.
Kaku K; Chin R; Naito Y; Iliev H; Ikeda R; Ochiai K; Yasui A
Expert Opin Drug Saf; 2020 Feb; 19(2):211-221. PubMed ID: 31769309
[No Abstract] [Full Text] [Related]
15. Cardiovascular Outcomes and Safety of Empagliflozin in Patients With Type 2 Diabetes Mellitus and Peripheral Artery Disease: A Subanalysis of EMPA-REG OUTCOME.
Verma S; Mazer CD; Al-Omran M; Inzucchi SE; Fitchett D; Hehnke U; George JT; Zinman B
Circulation; 2018 Jan; 137(4):405-407. PubMed ID: 29133602
[No Abstract] [Full Text] [Related]
16. Glucose Control and the Effect of Empagliflozin on Kidney Outcomes in Type 2 Diabetes: An Analysis From the EMPA-REG OUTCOME Trial.
Cooper ME; Inzucchi SE; Zinman B; Hantel S; von Eynatten M; Wanner C; Koitka-Weber A
Am J Kidney Dis; 2019 Nov; 74(5):713-715. PubMed ID: 31255334
[No Abstract] [Full Text] [Related]
17. A Randomized Trial of Empagliflozin to Increase Plasma Sodium Levels in Patients with the Syndrome of Inappropriate Antidiuresis.
Refardt J; Imber C; Sailer CO; Jeanloz N; Potasso L; Kutz A; Widmer A; Urwyler SA; Ebrahimi F; Vogt DR; Winzeler B; Christ-Crain M
J Am Soc Nephrol; 2020 Mar; 31(3):615-624. PubMed ID: 32019783
[TBL] [Abstract][Full Text] [Related]
18. Effect of Empagliflozin on the Metabolic Signature of Patients With Type 2 Diabetes Mellitus and Cardiovascular Disease.
Kappel BA; Lehrke M; Schütt K; Artati A; Adamski J; Lebherz C; Marx N
Circulation; 2017 Sep; 136(10):969-972. PubMed ID: 28874423
[No Abstract] [Full Text] [Related]
19. Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes.
Heise T; Seewaldt-Becker E; Macha S; Hantel S; Pinnetti S; Seman L; Woerle HJ
Diabetes Obes Metab; 2013 Jul; 15(7):613-21. PubMed ID: 23356556
[TBL] [Abstract][Full Text] [Related]
20. Empagliflozin's Ameliorating Effect on Plasma Triglycerides: Association with Endothelial Function Recovery in Diabetic Patients with Coronary Artery Disease.
Sawada T; Uzu K; Hashimoto N; Onishi T; Takaya T; Shimane A; Taniguchi Y; Yasaka Y; Ohara T; Kawai H
J Atheroscler Thromb; 2020 Jul; 27(7):644-656. PubMed ID: 31631099
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
